The U.S. Food and Drug Administration (FDA) announced a new program today that’s designed to foster close collaboration between public and private organizations in order to “bring coronavirus treatments to market as fast as possible,” according to U.S. Department of Health & Human Services Secretary Alex Azar in a press release.
Internally, the FDA has re-arranged staffing resources to help make this possible, putting medical and regulatory staff that otherwise would be focused elsewhere on teams dedicated to COVID-19-related reviews.
There’s likely to be some debate about the implications of the introduction of a program like this.
On the one hand, it should help novel approaches and even startups in the biotech space with unproven, but promising technologies in development to work hand-in-hand with the FDA on potential solutions.
The current coronavirus pandemic is unprecedented in terms of its spread and impact, at least in terms of viral outbreaks during the modern medical era.

Comments to: FDA introduces a new program to expedite deployment of potential coronavirus treatments – TechCrunch

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.